IONIS PHARMACEUTICALS INC 4

Director Spencer R. Berthelsen received a stock option grant for 5,369 shares at $79.19 and an award of 2,301 RSUs in Ionis Pharmaceuticals, Inc. as part of routine director compensation.

On July 1, 2026, non-employee director Spencer R. Berthelsen received routine equity compensation from Ionis Pharmaceuticals, Inc., consisting of a grant of 5,369 non-qualified stock options with an exercise price of $79.19 per share and a grant of 2,301 restricted stock units, both structured to vest 100% on the earlier of the first anniversary of grant or the next annual meeting of stockholders. These awards, made under the company’s Non-Employee Director compensation framework and capped so that his 2026 annual equity compensation does not exceed $400,000 of grant-date fair value, increased his direct beneficial ownership of common stock-related interests to 7,521 shares (on an as-converted/settled basis). The options are not exercisable as of the grant date and the RSUs are unvested, so the economic value is contingent and based on future vesting and Ionis’s share price at exercise or settlement.

Filing Facts

CIK

874015

Ticker

IONS

Form

4

Source Type

sec

Accession

0000874015-26-000226

Alert Tier

5